Dr. Rosen is a world-renowned researcher in the field of bone metabolism. His laboratory focuses on the study of marrow adiposity and bone formation and he has over twenty years of experience with NIH-funded clinical trials. He directs MHIR’s physiology core, a key resource that provides whole body and cell phenotyping related to metabolic function. Dr. Rosen has served on numerous NIH review panels and as editor of scientific journals; he is currently an associate editor at the New England Journal of Medicine and is a standing member of the FDA Endocrinologic and Metabolic Diseases Advisory Committee.
Dr. Gridley has over thirty years of experience studying genes and pathways important for embryonic development in mammals, and the connections between mutations in these genes and congenital and acquired human disease. Dr. Gridley has served on numerous NIH review panels, has been Director of an institutional training grant in developmental genetics, and is the Director of the MHIR Center for Molecular Medicine and as Vice Chair of the MMC Institutional Review Board.
Dr. Emery has over 10 years of experience as a clinical and translational researcher. She has participated in the development and launch of over 30 study protocols involving human participants. Dr. Emery also serves as the Associate Lead of the Professional Development Core of the Northern New England Clinical and Translational Research (NNE-CTR) Network and has developed and implemented training programs for early clinical investigators and research navigators.
Affiliated Investigators
Dr. Brodsky is an Endocrinologist who studies clinical diabetes and metabolism. He is the Maine Principal Investigator on the national Vitamin D and type 2 Diabetes (D2d Study) which is evaluating whether Vitamin D supplementation forestalls the onset of diabetes in those with pre-diabetes. He also serves as Clinical Advisor on the COBRE in Mesenchymal and Neural Regulation of Metabolic Networks.
Dr. Cairns is a Pediatric Pulmonologist who directs MMC’s Pediatric Cystic Fibrosis Research Program. She oversees a range of clinical trials that evaluate the effectiveness of new therapies to treat cystic fibrosis in children.
Dr. Craig is a neonatal neurologist at MMC specializing in the care of newborn infants with neurological issues. Her research program focuses on the use of therapeutic hypothermia to improve developmental outcomes.
Dr. Ecker is a neurosurgeon, the Director of the Neuroscience Institute at Maine Medical Center and Principal Site Investigator on several aneurysm and stroke intervention clinical trials, including the national Swift-Prime Study, which treats stroke victims with a promising tool that removes clots from the brain immediately following stroke.
David J. Gagnon, PharmD, BCCCP, is a Critical Care Clinical Pharmacist at Maine Medical Center and clinician-researcher. He completed his pharmacy education at Northeastern University and post-graduate training at Tufts Medical Center (PGY-1) and Maine Medical Center (PGY-2). Dr. Gagnon is a Board Certified Critical Care Pharmacist (BCCCP) with a focus in Neurocritical Care.
Dr. Kramer is a cardiothoracic surgeon who serves as Associate Director of the MMC Blood Management Program. His research interests include neuropsychological changes associated with cardiopulmonary bypass, perioperative glucose and blood management and cardiac surgery associated with acute kidney injury.
Dr. Miesfeldt is the Medical Director for the Cancer Risk and Prevention Program at MMC. Her research focuses on improving access to cancer prevention and early detection among the underserved as well as genetic risks of cancer, the use of telegenetics as a model of care, and studies of biomarkers of breast cancer to improve early detection and treatment.
Dr. Rappold is chief of the division of acute care surgery at MMC who is studying the extremes of trauma and hemorrhagic shock and their impact on hemostasis and potential recovery.
Dr. Riker specializes in critical care and pulmonary medicine. He is currently the Maine Principal Investigator for the 12-site NIH clinical study for the Prevention and Early Treatment of Acute Lung Injury (PETAL) which seeks to develop innovative approaches to improve outcomes of patients at risk for Acute Respiratory Distress Syndrome. Dr. Riker also serves as chair of MMC’s Institutional Review Board.
Dr. Sawyer is the Co-Director of the Myocardial Biology & Heart Failure Research Lab and is the Chief of Cardiovascular Services at Maine Medical Center. His research centers on developing therapeutic strategies to enhance myocardial repair after injury.
Dr. Seder, is Director of the Division of Neuro-critical Medicine at MMC. He investigates ways to minimize brain injury following cardiac arrest and stroke. See www.setpoint2.org to learn more about Dr. Seder’s study.
Dr. Siegel, is a pediatric psychiatrist at Maine Behavioral Healthcare and Director of the Autism and Developmental Disorder Inpatient Research Collaborative. His research focus is on assessment and intervention for challenging behaviors in youth severely affected by Autism Spectrum Disorder.
Dr. Zuckerman is Director of the Adult Cystic Fibrosis Program at MMC. He has a longstanding interest in therapeutic development for cystic fibrosis, and has conducted clinical trials on gene therapy for cystic fibrosis, and on outpatient infection control in adult and pediatric cystic fibrosis programs. He currently collaborates on several projects to define best practices in cystic fibrosis care, including evaluation of novel biomarkers, use of probiotics, and risk factors for venous catheter complications.
